SEARCH

SEARCH BY CITATION

References

  • 1
    Sternberg CN, Donat SM, Bellmunt J et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69: 6279
  • 2
    Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859866
  • 3
    Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202206
  • 4
    Montie JE, Clark PE, Eisenberger MA et al. Bladder cancer. J Natl Compr Canc Netw 2009; 7: 839
  • 5
    Galsky MD, Hahn NM, Rosenberg J et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12: 211214
  • 6
    von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 30683077
  • 7
    David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 2007; 178: 451454
  • 8
    Matsushita K, Mahmoodi BK, Woodward M et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307: 19411951
  • 9
    Mertens LS, Meijer RP, Kerst JM et al. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer – a reasonable alternative for cisplatin unfit patients? J Urol 2012; 188: 11081113
  • 10
    Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506513
  • 11
    Canter D, Viterbo R, Kutikov A et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 2011; 77: 160165
  • 12
    Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006; 24: 30953100
  • 13
    Rinnab L, Straub M, Hautmann RE, Braendle E. Postoperative resorptive and excretory capacity of the ileal neobladder. BJU Int 2005; 95: 12891292